Home » Newsletters » BioWorld Science

BioWorld Science

July 8, 2021

View Archived Issues

Phase II trial evaluates CBP-201 for chronic rhinosinusitis with nasal polyps

FDA approves IND for phase I study of STP-707 in solid tumors

AstraZeneca initiates phase I/II study of AZD-0466 in advanced hematological malignancies

Novartis studies combination of VOB-560 and MIK-665 for advanced hematological malignancies

New TGF-beta inhibitor KS-356 improves experimental obesity, hepatic steatosis

Dual GIP/GLP-1 receptor agonist HISHS-2001 displays efficacy in type 2 diabetes model

Scientists describe new model of primary sclerosing cholangitis-associated cholangiocarcinoma

SciSparc to initiate phase II study of SCI-110 in patients with AD and agitation

Chinese researchers patent claudin 18.2-targeting ADCs

Roche discloses BRAF mutant inhibitors

Shaanxi Synthetic Pharmaceutical identifies new antibacterials

Chiesi Farmaceutici synthesizes new LPAR2 antagonists

Centivax patents CR-3022-derived antibodies for SARS-CoV-2

Researchers at University of Oxford initiate phase I study of HIVconsvX vaccine

To close or not to close: Astrocytes influence brain plasticity by controlling critical period

LY-3305677 is safe and shows body weight-lowering effect in FIH trial

CXD-101 demonstrates promising early clinical data in its China IND program

Atossa receives approval to open phase I/II study of AT-H201 in Australia

Dosing starts in phase I/II study of Moderna's quadrivalent seasonal flu mRNA vaccine

FDA clears IND for ASC-618 gene therapy for hemophilia A

AXA-1125 enhances insulin sensitivity in subjects with NAFLD and T2D

Ischemix awarded DoD funding to support phase I study of CMX-2043 for traumatic brain injury

Alterations in GRK5 disrupt cardiac function in murine model

Ysopia completes phase I study of Xla-1 for obesity and metabolic diseases

Batavia collaborates with RocketVax on SARS-CoV-2 vaccine candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...